8-K: Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market

Genprex, Inc. has entered into agreements for a $6.5 million registered direct offering of common stock and warrants, priced at-the-market under Nasdaq rules.

Summary

• Genprex, Inc. has announced a registered direct offering to sell 165,000 shares of common stock, pre-funded warrants for 1,377,112 shares, and warrants for 1,542,112 shares.
• The offering is priced at $4.215 per share and accompanying warrant, or $4.2149 per pre-funded warrant and accompanying warrant.
• The company expects to raise approximately $5.8 million in net proceeds after deducting fees and expenses, excluding any proceeds from warrant exercises.
• The net proceeds will be used for working capital and general corporate purposes.
• The offering is expected to close on or about March 21, 2024, subject to customary closing conditions.
• The company has agreed not to issue further shares or convertible securities for 60 days after the closing, with some exceptions, including at-the-market offerings above $8.00 per share.
• The company has also agreed not to engage in variable rate transactions for one year after the closing, with some exceptions.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the offering provides necessary capital, it also dilutes existing shareholders and includes restrictions on future financing. The at-the-market pricing is fair, but the overall impact is mixed.

Positives

• The offering provides Genprex with additional capital for working capital and general corporate purposes.
• The offering is priced at-the-market, which is generally considered a fair valuation.
• The company has secured a commitment for $6.5 million in gross proceeds, which will provide a significant boost to its financial position.
• The company has amended existing warrants to lower the exercise price and extend the expiration date, which may be beneficial to investors.

Negatives

• The offering will dilute existing shareholders' ownership.
• The company has agreed to a 60-day lock-up period on further issuances of shares or convertible securities, which may limit its flexibility.
• The company has also agreed to a one-year restriction on variable rate transactions, which may limit its ability to raise capital in the future.
• The placement agent fees and expenses will reduce the net proceeds from the offering.

Risks

• The company's financial position, market conditions, and other risks detailed in its filings with the SEC could impact the amount of proceeds from the offering.
• There is a risk that the company may not be able to use the net proceeds from the offering effectively.
• The company's stock price may be negatively impacted by the dilution from the offering.
• The company's ability to raise capital in the future may be limited by the restrictions on further issuances and variable rate transactions.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Industry Context

This offering is a common method for clinical-stage biotech companies to raise capital to fund their operations and research. The at-the-market pricing is typical for such offerings, and the lock-up and variable rate transaction restrictions are also common to protect investors.

Comparison to Industry Standards

• The structure of this offering, including the use of common stock, pre-funded warrants, and warrants, is typical for biotech companies raising capital.
• The placement agent fees of 7% cash and 1% management fee are within the typical range for such transactions.
• The lock-up period of 60 days is a standard practice to prevent immediate selling pressure on the stock.
• The one-year restriction on variable rate transactions is also a common measure to protect investors from potentially dilutive financing structures.
• Comparable companies that have recently conducted similar offerings include XOMA Corporation, which raised $25 million in a registered direct offering, and Agenus Inc., which raised $100 million in a similar offering. These companies also used a combination of common stock and warrants, and their offerings were also priced at-the-market.

Stakeholder Impact

• Shareholders will experience dilution of their ownership.
• The company will have additional capital to fund its operations and research.
• The company's ability to raise capital in the future may be limited by the restrictions on further issuances and variable rate transactions.
• The company's stock price may be negatively impacted by the dilution from the offering.

Next Steps

• The offering is expected to close on or about March 21, 2024, subject to customary closing conditions.
• The company will use the net proceeds for working capital and general corporate purposes.
• The company will need to manage its capital structure and comply with the restrictions on further issuances and variable rate transactions.

Key Dates

Keywords

registered direct offering, common stock, warrants, pre-funded warrants, capital raise, at-the-market, dilution, lock-up period, variable rate transaction, placement agent